Copyright
©The Author(s) 2024.
World J Nephrol. Dec 25, 2024; 13(4): 98709
Published online Dec 25, 2024. doi: 10.5527/wjn.v13.i4.98709
Published online Dec 25, 2024. doi: 10.5527/wjn.v13.i4.98709
Figure 3 Potential targets for IgA nephropathy based on findings from genetic wide association studies.
ETAR: Endothelin angiotensin inhibitor; SGLT2: Sodium-glucose cotransporter; MRA: Mineralocorticoid receptor antagonists; AP: Alternative pathway; LP: Lectin pathway; CP: Classical pathway.
- Citation: Salvadori M, Rosso G. What is new in the pathogenesis and treatment of IgA glomerulonephritis. World J Nephrol 2024; 13(4): 98709
- URL: https://www.wjgnet.com/2220-6124/full/v13/i4/98709.htm
- DOI: https://dx.doi.org/10.5527/wjn.v13.i4.98709